drugset / Trial / NCT05701800

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

NCT05701800

Phase 1/2 Active not recruiting 659 enrolled ModernaTX, Inc.
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.

Timeline

Start
2023-01-23
Primary completion
2026-06-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine Intramuscular
Subject mRNA-1468 Vaccine Intramuscular

Indications